Literature DB >> 23852331

Urate transporters in the genomic era.

Hiroyuki Sakurai1.   

Abstract

PURPOSE OF REVIEW: Recent advances in genome technology have provided us with a list of molecules affecting urate handling in humans, many of which are unlikely to be identified through traditional physiological approach alone. Although this article is focused on urate, this can be viewed as a successful model of genomics-physiology collaboration. RECENT
FINDINGS: URATv1/GLUT9 (SLC2A9) is shown to play a critical role in urate reabsorption at the proximal tubule, probably more prominent than its partner URAT1 (SLC22A12). The major site of action of ABCG2 (ABCG2), an influential urate secretion transporter, has been shown to be the intestine rather than the kidney proximal tubule. Accordingly, hypofunction of ABCG2 leads to increased fractional excretion of urate, a finding traditionally interpreted as overproduction hyperuricemia. Some SLC17 family members secrete urate in the kidney or intestine. OAT2 (SLC22A7) may take up urate from blood to the proximal tubular cell. In addition, how a common single-nucleotide polymorphisms in ABCG2 affects its function has been elucidated.
SUMMARY: A finer grained picture of urate handling in the human body is now emerging, which will help choosing novel targets for urate-lowering therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23852331     DOI: 10.1097/MNH.0b013e328363ffc8

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  17 in total

Review 1.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

Review 2.  What do drug transporters really do?

Authors:  Sanjay K Nigam
Journal:  Nat Rev Drug Discov       Date:  2014-12-05       Impact factor: 84.694

3.  Examining an Association of Single Nucleotide Polymorphisms with Hyperuricemia in Chinese Flight Attendants.

Authors:  Jianpin Ye; Zhiwei Zeng; Yuxian Chen; Zhenkun Wu; Qingwei Yang; Tao Sun
Journal:  Pharmgenomics Pers Med       Date:  2022-06-08

4.  Association of a polymorphism in a gene encoding a urate transporter with CKD progression.

Authors:  Alessandra Testa; Francesca Mallamaci; Belinda Spoto; Anna Pisano; Maria Cristina Sanguedolce; Giovanni Tripepi; Daniela Leonardis; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 8.237

5.  Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH.

Authors:  Kei Taniguchi; Yoshifuru Tamura; Takanori Kumagai; Shigeru Shibata; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2016-03-02       Impact factor: 2.801

6.  SIRT1 prevents hyperuricemia via the PGC-1α/PPARγ-ABCG2 pathway.

Authors:  Juan Wang; Xiao-Xia Zhu; Lei Liu; Yu Xue; Xue Yang; He-Jian Zou
Journal:  Endocrine       Date:  2016-03-29       Impact factor: 3.633

Review 7.  Time to target uric acid to retard CKD progression.

Authors:  Takanori Kumagai; Tatsuru Ota; Yoshifuru Tamura; Wen Xiu Chang; Shigeru Shibata; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

8.  Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes and nephropathy.

Authors:  Thomas A VanderJagt; Monica H Neugebauer; Marilee Morgan; Donald W Bowden; Vallabh O Shah
Journal:  World J Diabetes       Date:  2015-08-10

9.  Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters.

Authors:  Sanjay K Nigam; Wei Wu; Kevin T Bush; Melanie P Hoenig; Roland C Blantz; Vibha Bhatnagar
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-21       Impact factor: 8.237

Review 10.  Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy.

Authors:  Christian Mende
Journal:  Adv Ther       Date:  2015-12-09       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.